The prognostic significance of baseline levels of neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR) and systemic immune-inflammation index (SII) in patients with a diagnosis of biliary tract cancer (BTC).

Abstract

Biliary tract cancer (BTC) is a diverse group of diseases with defined anatomical subtypes. The prognosis is poor and treatments are limited with minimal survival benefit in patients diagnosed with advanced disease. There is a niche to develop readily-available biomarkers that adjunct the current prognostic evaluators that are used in clinical practice. Although modern techniques have helped identify novel biomarkers by use of genomic sequencing and liquid biopsy, these technologies are expensive and time-consuming. It is a developing field and discoveries at fundamental level have yet to find their way “from bench to bedside� in BTC. This project aims to add to the current knowledge by investigating the prognostic significance of baseline levels of neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR) and systemic immune-inflammation index (SII) in patients with a diagnosis of BTC, including all 4 subtypes (Intra-hepatic cholangiocarcinoma [IHC], extra-hepatic cholangiocarcinoma [EHC], ampulla of Vater carcinoma[AVC] and gall bladder carcinoma [GBC]) that were referred to The Christie NHS Foundation Trust between January 2012 and August 2017. In multivariate analysis NLR [HR= 1.34 (95%CI=1.07-1.68, p=0.01] and SII [1.57 (95%CI=1.20-2.04, p

Date of Award	1 Aug 2020
Original language	English
Awarding Institution	The University of Manchester
Supervisor	Juan Valle (Supervisor) & Mairead Mcnamara (Supervisor)